V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 20214010 | 20129621 | 1.7 | 48 | Neo-adjuvant (N) | 2017-10-31 | 2018-09-30 | Sorafenib | 02 | N | SORAFENIB | 101644129 |
| 20214012 | 20129622 | 1.69 | 73.4 | null | 2017-11-16 | 2018-02-18 | Trial Unspecified | 1 | Y | TRIAL | 101767452 |
| 20214014 | 20129623 | 1.63 | 78 | Curative (C) | 2018-04-07 | 2018-04-08 | EOX | 02 | null | OXALIPLATIN + RALTITREXED | 101530346 |
| 20214015 | 20129624 | 1.81 | 54 | Neo-adjuvant (N) | 2017-05-16 | 2017-05-30 | Oxaliplatin + Raltitrexed | N | N | OXALIPLATIN + RALTITREXED | 100574682 |
| 20214016 | 20129625 | 1.81 | 78.4 | 03 | 2019-09-21 | 2019-09-21 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100794647 |
| 20214021 | 20129626 | 0 | 86 | Palliative (P) | 2019-08-07 | 2019-08-08 | EOX | 02 | Y | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101543561 |
| 20214022 | 20129627 | 1.58 | 77.4 | Neo-adjuvant (N) | 2018-04-20 | 2018-04-21 | EOX | N | Y | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100116619 |
| 20214023 | 20129628 | 1.72 | 74 | Curative (C) | 2016-08-31 | 2016-09-01 | Cetuximab + FOLFIRI cycle 2 onwards | 1 | Y | CETUXIMAB + IRINOTECAN + MDG | 101514901 |
| 20214027 | 20129629 | 1.73 | 65.9 | Palliative (P) | null | 2016-12-25 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101660252 |
| 20214028 | 20129630 | 1.9 | 66.8 | Palliative (P) | null | 2017-05-31 | Capecitabine 35days + RT | N | N | CAPECITABINE + RT | 101419679 |
| 20214030 | 20129631 | 1.67 | 87 | Palliative (P) | 2018-11-22 | 2018-11-22 | EOX | 02 | N | OXALIPLATIN + RALTITREXED | 100966403 |
| 20214031 | 20129632 | 1.58 | 93 | Palliative (P) | 2016-03-03 | 2016-03-15 | Sorafenib | 02 | N | SORAFENIB | 101769882 |
| 20214033 | 20129633 | 1.54 | 100.2 | Palliative (P) | 2019-05-24 | 2019-05-25 | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100904150 |
| 20214034 | 20129634 | 1.71 | 63.8 | Palliative (P) | 2020-02-07 | 2020-02-07 | IRINOTECAN + MDG + PANITUMUMAB | N | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101700801 |
| 20214036 | 20129635 | 1.56 | 50.7 | Palliative (P) | null | 2017-02-09 | Oxaliplatin + Raltitrexed | N | N | OXALIPLATIN + RALTITREXED | 101172191 |
| 20214038 | 20129636 | 1.9 | 0 | Adjuvant (A) | 2020-05-20 | 2020-06-04 | EOX | N | N | SORAFENIB | 100413268 |
| 20214039 | 20129637 | 1.6 | 65.2 | Curative (C) | 2017-01-17 | 2017-01-24 | Trial Unspecified | 02 | Y | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 100271930 |
| 20214041 | 20129638 | 1.83 | 72.4 | Neo-adjuvant (N) | 2018-10-12 | 2018-10-14 | Sorafenib | 02 | N | SORAFENIB | 100571406 |
| 20214042 | 20129639 | 1.76 | 72 | Neo-adjuvant (N) | 2017-11-17 | 2017-11-24 | Sorafenib | N | N | CETUXIMAB + FLUOROURACIL + OXALIPLATIN | 101824379 |
| 20214047 | 20129640 | 1.57 | null | null | 2019-08-24 | 2019-08-24 | IRINOTECAN + MDG + PANITUMUMAB | N | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100326692 |
| 20214048 | 20129641 | 0 | null | null | 2020-08-01 | 2020-08-11 | CAPECITABINE + RT | N | null | CAPECITABINE + RT | 100027128 |
| 20214049 | 20129642 | 1.63 | 117 | Palliative (P) | 2018-11-09 | 2018-12-13 | EOX | N | N | EOX | 101243934 |
| 20214050 | 20129643 | 1.76 | 58.25 | Palliative (P) | 2019-12-24 | 2019-12-24 | Cetuximab + FOLFIRI cycle 2 onwards | N | N | EOX | 101656047 |
| 20214053 | 20129644 | 1.63 | 79.4 | null | 2019-12-25 | 2019-12-25 | Sorafenib | 02 | null | SORAFENIB | 101676990 |
| 20214054 | 20129645 | 1.75 | 64.7 | Palliative (P) | 2020-09-10 | 2020-09-17 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 101375904 |
| 20214055 | 20129646 | 1.75 | 63.3 | null | 2021-05-21 | 2021-06-02 | EOX | 02 | null | CETUXIMAB + IRINOTECAN + MDG | 101117768 |
| 20214056 | 20129647 | 1.57 | null | null | 2017-10-23 | 2018-12-10 | EOX | N | null | EOX | 100582631 |
| 20214058 | 20129648 | 1.75 | 61.2 | Palliative (P) | null | 2019-03-29 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100780576 |
| 20214059 | 20129649 | 1.66 | 0 | Palliative (P) | 2019-01-12 | 2019-01-20 | Capecitabine 42days + RT | N | N | CAPECITABINE + RT | 101849592 |
| 20214060 | 20129650 | 1.75 | 91 | null | 2017-04-15 | 2017-04-15 | EOX | N | null | EOX | 101161973 |
| 20214062 | 20129651 | 1.6 | 102.6 | Palliative (P) | 2019-11-12 | 2019-11-26 | Capecitabine 42days + RT | N | N | CAPECITABINE + RT | 100931402 |
| 20214063 | 20129652 | 1.8 | 102.9 | Palliative (P) | 2020-02-04 | 2020-02-22 | EOX | 2 | N | EOX | 100150716 |
| 20214065 | 20129653 | 1.57 | null | null | 2017-05-20 | 2017-05-20 | EOX | 2 | null | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101071623 |
| 20214066 | 20129654 | 1.6 | 85 | null | 2018-08-25 | 2018-10-28 | Trial Unspecified | 02 | null | TRIAL | 101842137 |
| 20214067 | 20129655 | 1.7 | 80.4 | Neo-adjuvant (N) | null | 2017-03-24 | Cetuximab + FOLFIRI cycle1 | 02 | N | CETUXIMAB + IRINOTECAN + MDG | 100726418 |
| 20214068 | 20129656 | null | 75.3 | null | 2018-06-02 | 2018-06-06 | Sorafenib | 02 | null | SORAFENIB | 100815352 |
| 20214069 | 20129657 | 1.41 | 61.4 | Curative (C) | 2018-05-19 | 2018-05-26 | CAPECITABINE + RT | 02 | Y | CAPECITABINE + RT | 100599960 |
| 20214072 | 20129658 | 1.6 | 0 | Neo-adjuvant (N) | 2018-09-03 | 2018-09-04 | Sorafenib | 02 | Y | SORAFENIB | 100901622 |
| 20214073 | 20129659 | 1.79 | 66 | Palliative (P) | 2016-01-20 | 2016-02-03 | EOX | N | N | EOX | 100561261 |
| 20214075 | 20129660 | 1.86 | 47 | Palliative (P) | null | 2018-05-18 | EOX | 02 | N | EOX | 100192236 |
| 20214076 | 20129661 | 1.69 | 50 | Palliative (P) | 2020-10-17 | 2020-10-20 | Oxaliplatin + Raltitrexed | 02 | N | OXALIPLATIN + RALTITREXED | 100385443 |
| 20214077 | 20129662 | null | 114.9 | Palliative (P) | 2021-05-03 | 2021-05-03 | Sorafenib | 1 | N | SORAFENIB | 100857754 |
| 20214079 | 20129663 | 1.65 | 70.6 | Palliative (P) | null | 2019-01-06 | Cetuximab + FOLFIRI cycle 2 onwards | 2 | N | CETUXIMAB + IRINOTECAN + MDG | 100349227 |
| 20214081 | 20129664 | 1.88 | 85.7 | Palliative (P) | 2020-02-03 | 2020-02-03 | EOX | 99 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 100828967 |
| 20214083 | 20129665 | 1.72 | 114.9 | Palliative (P) | 2019-10-08 | 2019-11-12 | IRINOTECAN + MDG + PANITUMUMAB | 02 | N | FLUOROURACIL + IRINOTECAN + PANITUMUMAB | 101634233 |
| 20214084 | 20129666 | 1.71 | 84.7 | Neo-adjuvant (N) | 2019-10-17 | 2019-10-17 | Sorafenib | 02 | Y | SORAFENIB | 101094184 |
| 20214086 | 20129667 | 1.72 | 59.7 | null | null | 2016-11-28 | Sorafenib | 1 | null | SORAFENIB | 101059181 |
| 20214088 | 20129668 | 1.62 | 106.5 | null | 2016-08-27 | 2016-09-11 | EOX | 02 | null | TRIAL | 100114378 |
| 20214089 | 20129669 | 1.78 | 59 | null | 2017-11-06 | 2017-11-09 | CETUXIMAB + IRINOTECAN + MDG | 02 | null | CETUXIMAB + IRINOTECAN + MDG | 100835127 |
| 20214091 | 20129670 | 0 | 87 | Palliative (P) | null | 2018-10-03 | Capecitabine 35days + RT | 02 | N | CAPECITABINE + RT | 101349148 |